Literature DB >> 17485028

Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment.

Kerry Siminoski1, William D Leslie, Heather Frame, Anthony Hodsman, Robert G Josse, Aliya Khan, Brian C Lentle, Jacques Levesque, David J Lyons, Giuseppe Tarulli, Jacques P Brown.   

Abstract

In June 2005, new Canadian recommendations for bone mineral density (BMD) reporting in postmenopausal women and older men were published by Osteoporosis Canada (formerly the Osteoporosis Society of Canada) and the Canadian Association of Radiologists. The recommendations were developed by a multidisciplinary working group that included the Canadian Panel of the International Society for Clinical Densitometry and were reviewed and endorsed by multiple stakeholders. Previous Canadian osteoporosis guidelines advised intervention based on an individual's World Health Organization category (normal, osteopenia, or osteoporosis) as a marker of relative fracture risk. In the new approach, an individual's 10-yr absolute fracture risk, rather than BMD alone, is used for fracture risk categorization. Absolute fracture risk is determined using not only BMD results, but also age, sex, fragility fracture history, and glucocorticoid use. A procedure is presented for estimating absolute 10-yr fracture risk in untreated individuals, leading to assigning an individual to 1 of 3 absolute fracture risk categories: low risk (<10% 10-yr fracture risk), moderate risk (10-20%), and high risk (>20%). We propose that an individual's absolute fracture risk category should be the basis for deciding on treatment and frequency of BMD monitoring.

Entities:  

Mesh:

Year:  2007        PMID: 17485028     DOI: 10.1016/j.jocd.2007.01.001

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  28 in total

1.  Validation of a case definition for osteoporosis disease surveillance.

Authors:  W D Leslie; L M Lix; M S Yogendran
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

Review 2.  Development and use of FRAX in osteoporosis.

Authors:  J A Kanis; E V McCloskey; H Johansson; A Oden; O Ström; F Borgström
Journal:  Osteoporos Int       Date:  2010-05-13       Impact factor: 4.507

3.  NICE continues to muddy the waters of osteoporosis.

Authors:  J A Kanis; J E Compston
Journal:  Osteoporos Int       Date:  2008-06-05       Impact factor: 4.507

Review 4.  Our approach to osteoporosis screening and treatment needs to change.

Authors:  Mark S Cooper
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

5.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

6.  Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study.

Authors:  L-A Fraser; G Ioannidis; J D Adachi; L Pickard; S M Kaiser; J Prior; J P Brown; D A Hanley; W P Olszynski; T Anastassiades; S Jamal; R Josse; D Goltzman; A Papaioannou
Journal:  Osteoporos Int       Date:  2010-08-04       Impact factor: 4.507

Review 7.  PUFAs, Bone Mineral Density, and Fragility Fracture: Findings from Human Studies.

Authors:  Amanda B Longo; Wendy E Ward
Journal:  Adv Nutr       Date:  2016-03-15       Impact factor: 8.701

8.  Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

9.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

Review 10.  Prevention of osteoporosis-related fractures among postmenopausal women and older men.

Authors:  Poupak Rahmani; Suzanne Morin
Journal:  CMAJ       Date:  2009-10-19       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.